The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Large Will The Nanobody-Based Diagnostics Market Be By 2030 Compared To Its 2026 Market Size?
The nanobody-based diagnostics market has seen a rapid expansion in its size over recent years. It is anticipated to increase from $1.13 billion in 2025 to $1.27 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.7%. The market’s past growth is primarily due to advancements in antibody engineering technologies, a growing incidence of infectious diseases, increased demand for cancer diagnostics, higher research funding in immunodiagnostics, and the wider deployment of rapid diagnostic testing platforms.
The nanobody-based diagnostics market is anticipated to experience significant growth in the coming years. This market is projected to reach $2.07 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.0%. The expansion during the forecast period can be attributed to factors such as the increasing demand for precision diagnostics, the greater integration of AI-based assay analysis tools, the rising adoption of microfluidic biosensor systems, the growth of decentralized diagnostic testing, and an increasing focus on biomarkers for early disease detection. Key trends during this period include the growing acceptance of lateral flow nanobody assays, a rising need for high-affinity single-domain antibody reagents, the increasing incorporation of nanobodies into point-of-care diagnostics, the expansion of multiplexed biomarker detection platforms, and the growing application of nanobody-based imaging in disease monitoring.
Access Your Free Sample Report For In-Depth Market Analysis:
What Major Factors Are Driving The Nanobody-Based Diagnostics Market Forward?
The escalating occurrence of infectious diseases is anticipated to fuel the expansion of the nanobody based diagnostics market. These diseases are conditions caused by detrimental microorganisms like bacteria, viruses, fungi, or parasites, which can spread directly from person to person or indirectly through contact with tainted surroundings. The increase in infectious disease prevalence stems from greater human proximity, making it easier for pathogens to circulate within populations. Nanobody-based diagnostics play a crucial role by providing quick, highly specific, and sensitive detection of infectious agents, thereby enabling prompt diagnosis and treatment. This, in turn, helps manage the spread of such diseases and enhances patient recovery. For illustration, data from the Centers for Disease Control and Prevention, a US-based government agency, showed in March 2024 that tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, marking an increment of 1,295 cases. Consequently, the growing incidence of infectious diseases is a key factor propelling the nanobody based diagnostics market forward.
What Are The Main Segments Within The Nanobody-Based Diagnostics Market Segment Structure?
The nanobody-based diagnostics market covered in this report is segmented –
1) By Technology: Immunoassays, Molecular Diagnostics, Biosensor-Based Detection, Fluorescence And Imaging Diagnostics
2) By Product Type: Reagents, Kits, Instruments, Other Product Types
3) By Application: Infectious Diseases, Oncology, Autoimmune Disorders, Cardiovascular Diseases, Other Applications
4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Research Institutes, Other End Users
Subsegments:
1) By Immunoassays: Enzyme Linked Immunosorbent Assay, Western Blotting, Lateral Flow Assay, Radioimmunoassay
2) By Molecular Diagnostics: Polymerase Chain Reaction Based Assays, Nucleic Acid Hybridization, Next Generation Sequencing, Isothermal Amplification Techniques
3) By Biosensor Based Detection: Electrochemical Biosensors, Optical Biosensors, Piezoelectric Biosensors, Microfluidic Biosensors
4) By Fluorescence and Imaging Diagnostics: Fluorescence Microscopy, Flow Cytometry, Fluorescence In Situ Hybridization, Molecular Imaging Techniques
What Market Trends Are Affecting The Nanobody-Based Diagnostics Market?
Leading firms in the nanobody-based diagnostics market are concentrating on creating novel solutions, including sophisticated nanobody platforms, to enhance the precision and rapidity of identifying diseases. These advanced platforms employ compact, single-domain antibodies distinguished by their high specificity and stability, facilitating quicker tissue penetration, better targeting of disease biomarkers, and superior diagnostic and therapeutic efficacy when contrasted with traditional antibodies. A notable example is Cyclotek Pty Ltd, an Australia-based radiopharmaceutical firm, which received a CRC-P Round 16 grant from the Australian Government in September 2025, aimed at progressing a nanobody-based theranostic platform for cancer treatment. This initiative, undertaken in partnership with the University of Melbourne, Revela Bio Inc., and various local SMEs, is dedicated to crafting targeted diagnostics and therapeutics by utilizing nanobodies to target the Fibroblast Activation Protein (FAP), a biomarker extensively present in aggressive cancers like lung, pancreatic, and ovarian cancer. Nanobodies merge the accurate targeting capabilities of antibodies with the pharmacokinetic properties of small molecules, rendering them perfectly suited for both diagnostic imaging and therapeutic uses. The project’s objectives include creating sophisticated radiolabelling chemistry, performing pre-clinical assessments, and advancing to initial human clinical trials, thereby enabling Cyclotek Pty Ltd to expand and commercialize this groundbreaking platform throughout Australia, New Zealand, and the wider Asia-Pacific region.
Who Are The Companies Participating In The Nanobody-Based Diagnostics Market?
Major companies operating in the nanobody-based diagnostics market are Sanofi S.A., Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., PerkinElmer Inc., Bruker Corporation, Bio-Rad Laboratories Inc., GenScript Biotech Corporation, Biocytogen LLC, Sino Biological Inc., Abzena plc, NanoTemper Technologies GmbH, RayBiotech Inc., Proteintech Group Inc., Creative Biolabs Inc., Isogenica Ltd., Beroni Group Limited, Immudex ApS, Cyclotek Pty Ltd, NanoTag Biotechnologies GmbH.
Get The Full Nanobody-Based Diagnostics Market Report:
https://www.thebusinessresearchcompany.com/report/nanobody-based-diagnostics-market-report
Which Region Leads The Nanobody-Based Diagnostics Market In Overall Market Size?
North America was the largest region in the nanobody-based diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nanobody-based diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Nanobody-Based Diagnostics Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Nanobody-Based Diagnostics Market 2026, By The Business Research Company
pruritus therapeutic market report 2026
https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report
genomic urine testing market report 2026
https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report
ocular genetic diagnostic market report 2026
https://www.thebusinessresearchcompany.com/report/ocular-genetic-diagnostic-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model